TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Biocytogen Partners with BioCopy for Assessment and Potential Licensing of TCR-Mimic Antibodies

Tuesday, May 07, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a prominent biotechnology company specializing in novel antibody-based therapies, has announced a significant partnership with BioCopy AG (“BioCopy”), a research-focused biotech firm headquartered in Basel, Switzerland, regarding the evaluation and potential licensing of TCR-mimic antibodies.

Under the agreement, BioCopy gains access to fully human TCR-mimic antibodies directed against an intracellular antigen, sourced from Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct evaluations and holds the option to license these antibodies for the development of innovative cancer treatments.

Biocytogen, expressed optimism, stating, “We are pleased to provide BioCopy with our TCR-mimic antibodies. Our in vivo matured TCR-mimic antibodies have shown promising affinity and specificity. Teaming up with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we anticipate our collaboration will result in groundbreaking drugs for the benefit of cancer patients.”

BioCopy will use Biocytogen’s TCR-mimic antibodies to evaluate them against potential intracellular tumor-associated antigens. Leveraging its automated platform for optimizing multispecific biotherapeutics, BioCopy aims to advance these TCR-mimic antibodies into cutting-edge oncological treatments.

Biocytogen’s TCR-mimic platform focuses on discovering fully human antibodies targeting intracellular antigens presented on cell surfaces by MHC class I molecules. Utilizing proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization techniques, Biocytogen’s platform generates TCR-mimic antibodies highly specific for peptide/HLA complexes, distinct from HLA itself. Through high-throughput antibody screening, Biocytogen rapidly identifies TCR-mimic antibodies surpassing the specificity and affinity of endogenous TCRs from patients, addressing tumor immune evasion. Currently, antibody candidates for various intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are undergoing evaluation. Fully human antibody sequences derived from the TCR-mimic platform hold potential for empowering the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit